A serial dilution study of gadolinium-based MR imaging contrast agents

Area of Science:

• Radiology and Imaging Science
• Medical Physics
• Pharmacology

Background:

• Introduction of higher relaxivity MR contrast agents like gadobenate dimeglumine.
• Need for in vitro validation of efficacy and safety compared to existing agents.

Purpose of the Study:

• To demonstrate in vitro differences between various gadolinium-based contrast agents.
• To confirm previously published relaxivity values.
• To aid in optimizing MRI imaging sequences.

Main Methods:

• Creation of a contrast phantom with serial dilutions of 5 FDA-approved gadolinium-based contrast agents.
• Inclusion of dilution factors from 1:8 to 1:4096.
• Performance of spin-echo sequences at 1.5T and 3T with varying repetition times (TRs) and echo times (TEs).

Main Results:

• Gadobenate dimeglumine demonstrated the highest signal intensities at physiologic concentrations with short TRs/TEs, confirming higher R1 relaxivity.
• At higher concentrations and with longer TR/TE values, gadobenate dimeglumine showed the greatest signal intensity loss, confirming higher R2 relaxivity.

Conclusions:

• Rigorous in vitro methodology and serial dilution confirmed higher R1 and R2 relaxivities for gadobenate dimeglumine.
• Findings validated at both 1.5T and 3T magnetic field strengths.
• Supports the superior performance of gadobenate dimeglumine and informs imaging protocol optimization.